Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL644115 | 0.89 | TDP1 (0.58) | TDP1ATML3MBTL1KDM4EMEN1 | |
| SCHEMBL29941922 | 0.89 | TDP1 (0.58) | TDP1ATML3MBTL1KDM4EMEN1 | |
| SCHEMBL9468274 | 0.85 | TDP1 (0.55) | TDP1ATML3MBTL1KDM4EMEN1 | |
| SCHEMBL10500417 | 0.85 | TDP1 (0.55) | TDP1ATML3MBTL1KDM4EPPARG | |
| SCHEMBL28875517 | 0.84 | TDP1 (0.54) | TDP1ATML3MBTL1KDM4EPPARG | |
| SCHEMBL3079343 | 0.84 | TDP1 (0.54) | TDP1ATML3MBTL1KDM4EMEN1 | |
| SCHEMBL14359740 | 0.84 | TDP1 (0.54) | TDP1ATML3MBTL1KDM4EMEN1 | |
| SCHEMBL2996036 | 0.82 | ATM (0.53) | TDP1ATML3MBTL1KDM4EMEN1 | |
| SCHEMBL4644205 | 0.82 | KMT2A (0.54) | ATML3MBTL1KDM4EMEN1RECQL | |
| SCHEMBL241599 | 0.81 | TDP1 (0.58) | TDP1ATML3MBTL1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0863136-B1 | Derivatives of azetidine and pyrrolidine | AKZO NOBEL NV (NL) | 2003-09-24 | — | — | EP | disclosed |
| US-6403573-B1 | BICYCLIC-CARBO OR HETERO OXY OR BICYCLIC CARBO OR HETERO SULFIDE CONTAINING PYRROLIDINE/AZETIDINE DERIVATIVES USED AS ANTIDEPRESSANT OR PREVENTING SEROTONIN-RELATED DISEASES | AKZO NOBEL N.V. (NL) | 2002-06-11 | — | — | US | disclosed |
| US-20020040016-A1 | Derivatives of azetidine and pyrrolidine | MERCK SHARP & DOHME B.V. (NL) | 2002-04-04 | — | — | US | disclosed |
| US-6281243-B1 | ANTIDEPRESSANTS, ANTISEROTONINE AGENT | AKZO NOBEL N.V. (NL) | 2001-08-28 | — | — | US | disclosed |
| WO-1999043647-A1 | DERIVATIVES OF AZETIDINE AND PYRROLIDINE | AKZO NOBEL N.V. (NL) | 1999-09-02 | — | — | WO | disclosed |
| EP-0863136-A1 | Derivatives of azetidine and pyrrolidine | Akzo Nobel N.V. (NL) | 1998-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040016-A1 | Derivatives of azetidine and pyrrolidine | TPH1, TPH2, HTR1D | TDP1 1400/4885ATM 4756/4885L3MBTL1 4418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.